Photo from Piet Ost/X
May 8, 2024, 02:11
Piet Ost: RADIOSA trial at ESTRO24
Piet Ost, Assistant Professor of Radiation Oncology at Ghent University, shared on X/Twitter:
“RADIOSA trial:
- oligorecurrent PCa SBRT vs SBRT + 6 months ADT
- ADT improved bRFS and cRFS
- more polymetastatic recurrences in the ADT arm.
- would love to see eugonad-relapse free survival.
- will be interesting to see QoL data and compare with the DART trial.
ESTRO24.”
Source: Piet Ost/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 09:22
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12